Sofosbuvir Plus Ribavirin Without Interferon For Treatment of Acute HCV in HIV-1 Infected Individuals (SWIFT-C)

Trial Profile

Sofosbuvir Plus Ribavirin Without Interferon For Treatment of Acute HCV in HIV-1 Infected Individuals (SWIFT-C)

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs Ledipasvir/sofosbuvir (Primary) ; Sofosbuvir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SWIFT-C
  • Most Recent Events

    • 24 Oct 2017 Results assessing 8 weeks of ledipasvir/sofosbuvir therapy in HIV-infected men with genotype 1 or 4 HCV infection, of the presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
    • 14 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top